9 August 2017 - NICE has completed its appraisal of cabozantinib maleate for patients with previously treated advanced renal cell carcinoma.

Cabozantinib maleate is recommended, within its marketing authorisation, as an option for treating advanced renal cell carcinoma in adults after vascular endothelial growth factor targeted therapy, only if the company provides cabozantinib maleate with the discount agreed in the patient access scheme.

Read NICE Final Appraisal Determination for cabozantinib maleate

Read The Lancet Oncology news article